Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03785249
Title Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1
Recruitment Recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Mirati Therapeutics Inc.
Indications

Advanced Solid Tumor

Therapies

Adagrasib

Adagrasib + Afatinib

Adagrasib + Cetuximab

Adagrasib + Pembrolizumab

Age Groups: senior | adult
Covered Countries USA


No variant requirements are available.